Hypoglycemia - Harrison's Principles of Internal Medicine, 22nd Edition (Chapter 418)

1. DEFINITION

1. Symptoms consistent with hypoglycemia
2. A low plasma glucose concentration measured with a precise method
3. Relief of symptoms after the plasma glucose level is raised

2. GLUCOSE COUNTERREGULATION (Pathophysiology Basis)

Normal Counterregulatory Hierarchy (glucose thresholds in descending order):

Key counterregulatory hormones:

• Glucagon (first-line, from pancreatic alpha cells) - stimulates glycogenolysis and gluconeogenesis
• Epinephrine (critical when glucagon is deficient) - stimulates hepatic glucose production, limits glucose utilization, and provides warning symptoms
• Cortisol and growth hormone - important for recovery from prolonged hypoglycemia but not rapid acute defense

3. CAUSES (Table 418-1, Harrison's)

A. Ill or Medicated Individuals

• Insulin or insulin secretagogues (sulfonylureas, meglitinides)
• Alcohol - inhibits gluconeogenesis; occurs after binge drinking with inadequate food intake
• Others: quinine, pentamidine, quinolones, indomethacin, beta-blockers (mask symptoms), ACE inhibitors, IGF-1

• Hepatic failure (reduced glycogen stores + impaired gluconeogenesis)
• Renal failure (reduced renal gluconeogenesis + reduced insulin clearance)
• Cardiac failure (hepatic congestion)
• Sepsis (increased peripheral glucose consumption, cytokine-mediated insulin release)
• Inanition (prolonged starvation)

• Cortisol deficiency (Addison's disease, hypopituitarism) - reduces gluconeogenic substrates and limits epinephrine-stimulated glucose production
• Growth hormone deficiency
• Glucagon + epinephrine deficiency (seen in insulin-deficient diabetes)

• Large mesenchymal/epithelial tumors (e.g., fibrosarcoma, hepatocellular carcinoma)
• Cause hypoglycemia via excess secretion of incompletely processed (big) IGF-II, which activates insulin receptors

B. Seemingly Well Individuals

• Insulinoma - most common surgically correctable cause; ~90% benign, solitary pancreatic beta-cell tumor
• Functional beta-cell disorders (nesidioblastosis)
• Noninsulinoma pancreatogenous hypoglycemia (NIPHS)
• Post-gastric bypass hypoglycemia (postprandial, typically within 1-3 hours; due to exaggerated GLP-1 response and postprandial hyperinsulinism)
• Insulin autoimmune hypoglycemia - antibodies to insulin or insulin receptor
• Antibody to insulin receptor
• Ectopic insulin secretion (very rare)

• Hyperinsulinism of infancy (mutations in KATP channel genes: ABCC8/KCNJ11)
• Glucokinase-activating mutations
• Fatty acid oxidation defects
• Glycogen storage diseases
• Gluconeogenic enzyme deficiencies

• Surreptitious insulin or sulfonylurea use (healthcare workers, patients with psychiatric disorders)

4. PATHOPHYSIOLOGY

In Diabetic Patients - Hypoglycemia-Associated Autonomic Failure (HAAF)

• Relative or absolute therapeutic insulin excess
• Compromised glucose counterregulation

• T1DM early: Glucagon response to hypoglycemia is lost (because glucagon secretion is normally suppressed by local insulin from beta cells - which are now absent)
• T1DM long-standing + Advanced T2DM: Both glucagon AND epinephrine responses are impaired
• This creates defective glucose counterregulation - the patient cannot mount adequate defense against falling glucose

HAAF Cycle (shown in flowchart below):

• Attenuated adrenomedullary epinephrine responses → Defective glucose counterregulation
• Attenuated sympathetic neural responses → Hypoglycemia unawareness
• Both together → Recurrent hypoglycemia - creating a vicious cycle

5. CLINICAL FEATURES

A. Neurogenic (Autonomic) Symptoms

• Tremor (adrenergic)
• Palpitations (adrenergic)
• Anxiety (adrenergic)
• Sweating (cholinergic)
• Hunger (cholinergic)
• Paresthesias (cholinergic)

B. Neuroglycopenic Symptoms

• Cognitive impairment / difficulty concentrating
• Confusion / behavioral changes
• Fatigue and weakness
• Seizure
• Loss of consciousness / coma
• Focal neurologic deficits (transient hemiplegia, aphasia - rare)
• At very low levels (<1.1 mmol/L): coma and death

Clinical Note:

• In patients with hypoglycemia unawareness (HAAF), neuroglycopenic symptoms may appear WITHOUT prior neurogenic warning symptoms
• Nocturnal hypoglycemia may be asymptomatic (patient asleep) and present as morning headache, wet sheets, or waking with confusion

6. INVESTIGATIONS

A. Confirming Hypoglycemia (Whipple's Triad)

• Plasma glucose (venous sample by glucose oxidase method - NOT capillary fingerstick alone): confirmed <70 mg/dL during symptoms, with relief on glucose administration

B. Initial Workup (done when Whipple's triad is confirmed or during fasting test)

C. The 72-Hour Supervised Fast

• Insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and glucose measured every 6 hours (every 1-2 hours when glucose falls <60 mg/dL)
• Fast is ended when:
  • Plasma glucose falls to <45 mg/dL AND patient has symptoms, OR
  • After 72 hours without hypoglycemia (essentially excludes insulinoma)
• At the end: give IV glucagon 1 mg - a plasma glucose rise of >25 mg/dL confirms insulin-mediated hypoglycemia

D. Localization Studies (if endogenous hyperinsulinism confirmed)

• CT/MRI of the pancreas - first-line; 70-80% sensitivity for insulinoma
• Endoscopic ultrasound (EUS) - high sensitivity (80-90%); can detect tumors <1 cm
• Somatostatin receptor scintigraphy (SRS/octreotide scan) - useful for non-beta-cell tumors
• Selective arterial calcium stimulation test (SACST) - intra-arterial calcium injection into feeding arteries with hepatic vein insulin sampling; regionalizes hyperfunctioning tissue
• Intraoperative ultrasound - gold standard for localizing at surgery

E. For Non-Islet Cell Tumors

• Serum IGF-II, IGF-I, and IGFBP-3
• "Big IGF-II" (high molecular weight precursor form) - confirmatory
• Imaging (CT/MRI) for large tumor identification

F. For Post-Gastric Bypass Hypoglycemia

• Mixed meal test (reproduces postprandial symptoms): measure glucose, insulin, C-peptide, and GLP-1 every 30 min for 5 hours
• 72-hour fast typically does NOT induce hypoglycemia (helps distinguish from insulinoma)

7. MANAGEMENT

A. Acute Treatment

• 15-20 g fast-acting oral carbohydrate: 4 glucose tablets, 120-180 mL fruit juice, regular soft drink, or glucose gel
• Recheck glucose in 15 minutes; repeat if still <70 mg/dL
• Follow with a snack containing complex carbohydrate + protein once glucose has normalized (prevents recurrence)

• IV dextrose: 25 g (50 mL of 50% dextrose) IV push, followed by 5% or 10% dextrose infusion to maintain glucose >100 mg/dL
• Glucagon IM/SC: 1 mg (adult); effective when IV access is unavailable; acts within 10-15 min by stimulating hepatic glycogenolysis
  • Less effective in: prolonged fasting/starvation (depleted glycogen stores), alcohol-induced hypoglycemia, adrenal insufficiency
• Nasal glucagon (3 mg) is now approved as an alternative to IM glucagon for home use

• Identify and treat the underlying cause
• Monitor glucose until the patient is stable and eating
• For long-acting insulin or sulfonylurea-induced hypoglycemia: prolonged dextrose infusion may be needed (sulfonylureas may cause hypoglycemia for 24-48+ hours)

B. Insulinoma Management

• Surgical resection (enucleation or partial pancreatectomy) - curative in ~90% of benign insulinomas
• Diazoxide - inhibits insulin secretion via opening of KATP channels; used preoperatively or for inoperable cases (dose 150-450 mg/day orally)
• Octreotide/lanreotide (somatostatin analogues) - used for metastatic insulinoma and some other causes
• Everolimus and sunitinib - approved for unresectable/metastatic pancreatic NETs (including insulinoma)

C. Non-Islet Cell Tumor Hypoglycemia

• Primary treatment: reduce tumor burden (surgery, embolization, chemotherapy)
• Glucocorticoids (prednisone 30-60 mg/day) and/or growth hormone can alleviate hypoglycemia by increasing glucose production and antagonizing IGF-II effects
• Frequent small meals and continuous nasogastric glucose infusion (palliative)

D. Post-Gastric Bypass Hypoglycemia

• Dietary modification - small, low-carbohydrate meals; avoid rapidly absorbed carbohydrates
• Acarbose (alpha-glucosidase inhibitor) - slows carbohydrate absorption, reduces postprandial glucose/insulin excursions
• Diazoxide or octreotide (if dietary measures fail)
• Calcium channel blockers (verapamil, nifedipine) - reduce insulin secretion
• Reversal of bypass (gastrostomy tube feeding) - in severe, refractory cases
• Partial pancreatectomy is generally NOT recommended (high recurrence)

E. Hypoglycemia in Diabetic Patients - Prevention and Risk Factor Reduction

• Identify and address risk factors: excessive insulin dose, missed/delayed meals, unplanned exercise, alcohol intake, renal/hepatic failure
• Relaxed glycemic targets in patients with HAAF, hypoglycemia unawareness, or comorbidities (HbA1c target ~8%)
• Structured patient education on hypoglycemia recognition and treatment
• Continuous glucose monitoring (CGM) with or without insulin pump (closed-loop systems) - shown to reduce hypoglycemia frequency
• Avoid beta-blockers when possible (mask adrenergic warning symptoms)
• Scrupulous avoidance of antecedent hypoglycemia for 2-3 weeks can restore hypoglycemia awareness in many patients (reversal of HAAF)

F. Adrenal Insufficiency as a Cause

• Hydrocortisone replacement - treats the underlying cause

8. PREVENTION OF RECURRENT HYPOGLYCEMIA

• Regimen adjustment (reduce insulin dose, change timing, switch to analog insulin)
• Patient education programs
• CGM use
• Strict avoidance of hypoglycemia for 2-3 weeks to restore hypoglycemia awareness

9. DIFFERENTIAL DIAGNOSIS

Conditions mimicking hypoglycemia:

Distinguishing Causes of True Hypoglycemia:

10. DIAGNOSTIC APPROACH (Harrison's Stepwise Approach)

• Yes → Investigate and correct excess insulin dosing, missed meals, drug interactions, organ failure
• No → Proceed to Step 3

• Ill → Think: critical illness (hepatic/renal/cardiac failure), sepsis, drugs, hormone deficiencies, non-beta-cell tumor. Treat the underlying illness.
• Seemingly well → Proceed to endogenous hyperinsulinism workup

• Fasting → Insulinoma, factitious, hormone deficiency, non-islet cell tumor → 72-hour fast with glucose/insulin/C-peptide/proinsulin/beta-hydroxybutyrate
• Postprandial → Post-gastric surgery hypoglycemia, NIPHS, reactive hypoglycemia → Mixed meal test

• Whipple's triad must be documented before extensive workup
• The 72-hour fast remains the gold standard for insulinoma diagnosis
• C-peptide is the key test to distinguish exogenous insulin injection (factitious) from endogenous causes
• HAAF and hypoglycemia unawareness create a dangerous vicious cycle - address by relaxing glycemic targets and avoiding antecedent hypoglycemia
• Glucagon IM is critical first-aid for severe hypoglycemia when IV access is unavailable
• Post-gastric bypass hypoglycemia is increasingly recognized and responds to dietary modification before pharmacologic intervention

Source: Harrison's Principles of Internal Medicine, 22nd Edition (2025, McGraw Hill) - Chapter 418: Hypoglycemia, Stephen N. Davis